X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare FDC LTD. with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. GLENMARK PHARMA FDC LTD./
GLENMARK PHARMA
 
P/E (TTM) x 16.0 10.6 150.6% View Chart
P/BV x 2.2 1.9 113.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FDC LTD.   GLENMARK PHARMA
EQUITY SHARE DATA
    FDC LTD.
Mar-18
GLENMARK PHARMA
Mar-18
FDC LTD./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs319930 34.3%   
Low Rs164517 31.7%   
Sales per share (Unadj.) Rs61.6322.6 19.1%  
Earnings per share (Unadj.) Rs9.928.5 34.9%  
Cash flow per share (Unadj.) Rs12.039.2 30.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs73.2183.0 40.0%  
Shares outstanding (eoy) m174.40282.17 61.8%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.92.2 174.6%   
Avg P/E ratio x24.325.4 95.6%  
P/CF ratio (eoy) x20.218.5 109.3%  
Price / Book Value ratio x3.34.0 83.5%  
Dividend payout %07.0 0.0%   
Avg Mkt Cap Rs m42,118204,206 20.6%   
No. of employees `0005.513.7 40.3%   
Total wages/salary Rs m2,16718,718 11.6%   
Avg. sales/employee Rs Th1,943.76,636.8 29.3%   
Avg. wages/employee Rs Th391.71,364.7 28.7%   
Avg. net profit/employee Rs Th313.7586.1 53.5%   
INCOME DATA
Net Sales Rs m10,75191,031 11.8%  
Other income Rs m510914 55.8%   
Total revenues Rs m11,26091,945 12.2%   
Gross profit Rs m2,26716,154 14.0%  
Depreciation Rs m3513,019 11.6%   
Interest Rs m142,856 0.5%   
Profit before tax Rs m2,41111,193 21.5%   
Minority Interest Rs m-50-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6713,155 21.3%   
Profit after tax Rs m1,7358,039 21.6%  
Gross profit margin %21.117.7 118.8%  
Effective tax rate %27.828.2 98.8%   
Net profit margin %16.18.8 182.8%  
BALANCE SHEET DATA
Current assets Rs m7,21369,887 10.3%   
Current liabilities Rs m2,10432,879 6.4%   
Net working cap to sales %47.540.7 116.9%  
Current ratio x3.42.1 161.3%  
Inventory Days Days5481 66.9%  
Debtors Days Days2893 29.7%  
Net fixed assets Rs m6,86528,892 23.8%   
Share capital Rs m175282 62.1%   
"Free" reserves Rs m12,58651,353 24.5%   
Net worth Rs m12,76151,635 24.7%   
Long term debt Rs m641,418 0.0%   
Total assets Rs m15,041125,954 11.9%  
Interest coverage x173.24.9 3,521.0%   
Debt to equity ratio x00.8 0.1%  
Sales to assets ratio x0.70.7 98.9%   
Return on assets %11.68.6 134.4%  
Return on equity %13.615.6 87.3%  
Return on capital %19.015.1 125.6%  
Exports to sales %12.30-   
Imports to sales %00-   
Exports (fob) Rs m1,327NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,88936,317 5.2%   
Fx outflow Rs m09,720 0.0%   
Net fx Rs m1,88926,598 7.1%   
CASH FLOW
From Operations Rs m1,49816,481 9.1%  
From Investments Rs m201-10,133 -2.0%  
From Financial Activity Rs m-1,694-4,685 36.2%  
Net Cashflow Rs m101,770 0.6%  

Share Holding

Indian Promoters % 68.9 48.3 142.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 6.9 68.1%  
FIIs % 7.5 34.4 21.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 10.5 181.0%  
Shareholders   23,730 56,727 41.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare FDC LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 267 Points Lower; Metal and Capital Goods Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Aug 21, 2019 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE FDC LTD. WITH

MARKET STATS